Huang Liyin, Lu Yanwen, Yi Lei, Zhao Yuxin, Si Tao, Zhang Mingmin
Liuzhou Traditional Chinese Medical Hospital, Liuzhou, Guangxi Zhuang Autonomous Region, China.
Guilin Traditional Chinese Medical Hospital, Guilin, Guangxi Zhuang Autonomous Region, China.
Discov Oncol. 2025 Jul 11;16(1):1309. doi: 10.1007/s12672-025-02402-9.
Tyrosine-Protein Kinase Src (SRC), a non-receptor tyrosine kinase encoded by the Src gene, plays a crucial role in cell growth, division, migration, and survival signaling pathways. Dysregulation of SRC expression and activity is associated with advanced stages of several human cancers and poor prognosis. However, the prognostic value of SRC across multiple cancers and its involvement in immune response remain unclear. Therefore, this study aimed to investigate the relationship between SRC expression levels and cancer patient prognosis, as well as its potential impact on the immune microenvironment.
In this study, we utilized the Sangerbox database to investigate the differential expression of SRC in various types of cancer tumors and adjacent normal tissues. Survival outcomes of SRC expression levels in pan cancer were analyzed by Cox risk ratio and Kaplan Meier analysis. We further explored the relationship between SRC expression and immune regulatory genes, tumor mutation load, microsatellite instability, and the immune microenvironment of pan cancer using the Sangerbox database.
Compared to normal tissues, SRC expression is upregulated in various tumor tissues. SRC is significantly correlated with OS and in tumors such as LIHC and PRAD. Furthermore, SRC expression is significantly associated with mutation burden and microsatellite instability in tumors such as LUAD and COAD. In addition, SRC expression is related to the abundance of infiltrating immune cells in tumors such as LIHC and PRAD. These findings suggest that SRC may serve as a potential prognostic biomarker and therapeutic target for various cancers, and may be associated with the immune microenvironment of tumors.
Our results suggest that SRC may play a role in regulating immune infiltration and impacting the prognosis of cancer patients, highlighting its potential as a therapeutic target and biomarker for various cancers.
酪氨酸蛋白激酶Src(SRC)是一种由Src基因编码的非受体酪氨酸激酶,在细胞生长、分裂、迁移和生存信号通路中起关键作用。SRC表达和活性的失调与几种人类癌症的晚期阶段及不良预后相关。然而,SRC在多种癌症中的预后价值及其在免疫反应中的作用仍不清楚。因此,本研究旨在探讨SRC表达水平与癌症患者预后之间的关系,以及其对免疫微环境的潜在影响。
在本研究中,我们利用Sangerbox数据库研究SRC在各种类型癌症肿瘤及相邻正常组织中的差异表达。通过Cox风险比和Kaplan Meier分析评估泛癌中SRC表达水平的生存结果。我们还利用Sangerbox数据库进一步探讨了SRC表达与免疫调节基因、肿瘤突变负荷、微卫星不稳定性以及泛癌免疫微环境之间的关系。
与正常组织相比,SRC在各种肿瘤组织中表达上调。SRC与总生存期显著相关,在肝癌(LIHC)和前列腺癌(PRAD)等肿瘤中也是如此。此外,在肺腺癌(LUAD)和结肠癌(COAD)等肿瘤中,SRC表达与突变负担和微卫星不稳定性显著相关。另外,在LIHC和PRAD等肿瘤中,SRC表达与浸润免疫细胞的丰度有关。这些发现表明,SRC可能是各种癌症潜在的预后生物标志物和治疗靶点,并且可能与肿瘤的免疫微环境有关。
我们的结果表明,SRC可能在调节免疫浸润和影响癌症患者预后方面发挥作用,突出了其作为各种癌症治疗靶点和生物标志物的潜力。